Molecular Templates, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Net Income (Loss) Per Common Share (Tables)

Net Income (Loss) Per Common Share (Tables)

6 Months Ended

Jun. 30, 2013

Reconciliation of Numerator and Denominator

A reconciliation of the numerator and denominator used in the calculation is as follows (in thousands, except per share amounts):


	Three Months Ended June 30,						Six Months Ended June 30,
	2013			2012			2013			2012
Numerator:
Net income (loss) - basic	$	(12,788	)	$	17,001		$	(22,002	)	$	(98,532	)
Less: noncash income from change in fair value of common stock warrants		—			(19,852	)		—			—

Net loss - diluted		(12,788	)		(2,851	)		(22,002	)		(98,532	)

Denominator:
Weighted average common shares outstanding		57,037			54,549			56,763			52,435
Dilutive effect of warrants		—			8,945			—			—

Weighted-average common shares outstanding and potential dilutive common shares - diluted		57,037			63,494			56,763			52,435

Net income (loss) per share
Basic	$	(0.22	)	$	0.31		$	(0.39	)	$	(1.88	)

Diluted	$	(0.22	)	$	(0.04	)	$	(0.39	)	$	(1.88	)

Warrants, Options and Purchase Rights Excluded from Computation of Diluted Net Loss Per Share

The following outstanding warrants, options and purchase rights under the Company’s 2004 Employee Stock Purchase Plan were excluded from the computation of diluted net loss per share for the periods presented because including them would have had an antidilutive effect. The amounts disclosed below are prior to the application of the treasury stock method (in thousands):


	Three Months Ended June 30,				Six Months Ended June 30,
	2013		2012		2013		2012
Shares issuable upon exercise of warrants		9,634		—		9,634		12,615
Shares issuable upon exercise of stock options		6,570		5,072		6,570		5,072
Shares issuable related to the ESPP		85		79		85		79